Aerovate Therapeutics, Inc.

NasdaqGM:AVTE 株式レポート

時価総額:US$59.5m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Aerovate Therapeutics マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Tim Noyes

最高経営責任者

US$3.1m

報酬総額

CEO給与比率19.1%
CEO在任期間3.3yrs
CEOの所有権n/a
経営陣の平均在職期間2.8yrs
取締役会の平均在任期間3.4yrs

経営陣の近況

Recent updates

Here's Why Aerovate Therapeutics (NASDAQ:AVTE) Must Use Its Cash Wisely

Oct 01
Here's Why Aerovate Therapeutics (NASDAQ:AVTE) Must Use Its Cash Wisely

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Jun 11

Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

May 24
Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Feb 09
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Oct 17
We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Jul 04
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

Feb 28
Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Jan 06
A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Oct 14
Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

Jul 01
Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

Jan 22
We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

Sep 30
Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

CEO報酬分析

Aerovate Therapeutics の収益と比較して、Tim Noyes の報酬はどのように変化したか?
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$88m

Mar 31 2024n/an/a

-US$82m

Dec 31 2023US$3mUS$586k

-US$76m

Sep 30 2023n/an/a

-US$70m

Jun 30 2023n/an/a

-US$64m

Mar 31 2023n/an/a

-US$57m

Dec 31 2022US$704kUS$563k

-US$52m

Sep 30 2022n/an/a

-US$45m

Jun 30 2022n/an/a

-US$37m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$5mUS$437k

-US$23m

報酬と市場: Timの 総報酬 ($USD 3.07M ) は、 US市場 ($USD 681.57K ) の同規模の企業の平均を上回っています。

報酬と収益: Timの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Tim Noyes (62 yo)

3.3yrs

在職期間

US$3,070,657

報酬

Mr. Timothy P. Noyes, MBA, also known as Tim, has been the Chief Executive Officer of Aerovate Therapeutics, Inc. since May 2021 and has been its Director since April 2021. Mr. Noyes serves as Venture Part...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Timothy Noyes
CEO & Director3.3yrsUS$3.07mデータなし
George Eldridge
CFO & Treasurer3.5yrsUS$2.13m0.017%
$ 10.3k
Timothy Pigot
Chief Commercial Officer3.3yrsUS$2.45m0.011%
$ 6.7k
Benjamin Dake
Founder6.2yrsUS$2.88m0.049%
$ 29.4k
Marinus Verwijs
Chief Technical Officer1.3yrsUS$1.32mデータなし
Ralph Niven
Chief Scientific Officer2.1yrsUS$433.20k0.0056%
$ 3.3k
Hunter Gillies
Chief Medical Officer4.3yrsUS$1.63m0.019%
$ 11.5k
Donna Dea
Head of Regulatory Affairs4yrsデータなしデータなし
Susan Fischer
Executive Vice President of Development Operations2.4yrsデータなしデータなし
Stephen Yu
Senior Vice President of Quality2.1yrsデータなしデータなし
Sanjeev Khindri
Executive Vice President of Clinical Development1.7yrsデータなしデータなし
Cheryl Lassen
Senior Vice President of Clinical Development1.7yrsデータなしデータなし

2.8yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: AVTEの経営陣は 経験豊富 であると考えられます ( 2.8年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Timothy Noyes
CEO & Director3.4yrsUS$3.07mデータなし
Maha Katabi
Independent Director4.1yrsUS$230.01k0%
$ 0
Christian Schade
Independent Director1.2yrsデータなしデータなし
Donald Santel
Independent Director1.7yrsUS$568.54k0%
$ 0
David Grayzel
Independent Director4.1yrsUS$225.99k0%
$ 0
Joshua Resnick
Independent Director4.1yrsUS$174.80k0%
$ 0
Mark Iwicki
Independent Director3.6yrsUS$218.30k0%
$ 0
Allison Dorval
Independent Director3.2yrsUS$185.80k0%
$ 0
Habib Dable
Independent Chairman of the Board1.2yrsUS$363.25k0%
$ 0

3.4yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: AVTEの 取締役会経験豊富 であると考えられます ( 3.3年の平均在任期間)。